Outlook Therapeutics Inc News - OTLKW

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and...

Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock

ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook...

Current Report Filing (8-k)

0001649989 false 0001649989 2021-11-16 2021-11-16 0001649989 us-gaap:CommonStockMember 2021-11-16 2021-11-16 0001649989 otlk:SeriesAW...

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical...

Outlook Therapeutics to Present at the Virtual Investor Roundtable Event

ISELIN, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference

ISELIN, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases

ISELIN, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab

ISELIN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

ISELIN, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

ISELIN, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior...

Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

ISELIN, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW)

Professional-Grade Tools, for Individual Investors.

OTLKW News

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock

Current Report Filing (8-k)

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

Outlook Therapeutics to Present at the Virtual Investor Roundtable Event

Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference

Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases

Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

OTLKW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW) News

Outlook Therapeutics Inc (OTLKW)

Professional-Grade Tools, for Individual Investors.

OTLKW News

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock

Current Report Filing (8-k)

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

Outlook Therapeutics to Present at the Virtual Investor Roundtable Event

Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference

Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases

Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

OTLKW Discussion

Your Recent History